These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27822748)

  • 1. Suppression of Ehrlich carcinoma growth by cobra venom factor.
    Terpinskaya TI; Ulashchik VS; Osipov AV; Tsetlin VI; Utkin YN
    Dokl Biol Sci; 2016 Sep; 470(1):240-243. PubMed ID: 27822748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cobra Venom Factor and Ketoprofen Abolish the Antitumor Effect of Nerve Growth Factor from Cobra Venom.
    Osipov AV; Terpinskaya TI; Kuznetsova TE; Ryzhkovskaya EL; Lukashevich VS; Rudnichenko JA; Ulashchyk VS; Starkov VG; Utkin YN
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28878143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor from cobra venom inhibits the growth of Ehrlich tumor in mice.
    Osipov AV; Terpinskaya TI; Kryukova EV; Ulaschik VS; Paulovets LV; Petrova EA; Blagun EV; Starkov VG; Utkin YN
    Toxins (Basel); 2014 Feb; 6(3):784-95. PubMed ID: 24577582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve growth factor suppresses Ehrlich carcinoma growth.
    Osipov AV; Terpinskaya TI; Ulaschik VS; Tsetlin VI; Utkin YN
    Dokl Biochem Biophys; 2013; 451():207-8. PubMed ID: 23975402
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
    Vogel CW; Fritzinger DC
    Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
    Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
    Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
    Vogel CW; Finnegan PW; Fritzinger DC
    Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of complement C3 might rescue vascular hyporeactivity in a conscious hemorrhagic shock rat model.
    Chen D; Song MQ; Liu YJ; Xue YK; Cheng P; Zheng H; Chen LB
    Microvasc Res; 2016 May; 105():23-9. PubMed ID: 26687560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role and mechanism of cobra venom factor-induced suppression of the humoral immune response in guinea pigs.
    Böttger EC; Hoffmann T; Metzger S; Hadding U; Bitter-Suermann D
    J Immunol; 1986 Aug; 137(4):1280-5. PubMed ID: 2942603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.
    El-Naa MM; Othman M; Younes S
    Drug Des Devel Ther; 2016; 10():3661-3672. PubMed ID: 27895461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors in cobra venoms affecting the complement system.
    Vogt W
    Toxicon; 1982; 20(1):299-303. PubMed ID: 7080043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of native and recombinant cobra venom factor using thiophilic adsorption chromatography.
    Kölln J; Braren I; Bredehorst R; Spillner E
    Protein Pept Lett; 2007; 14(5):475-80. PubMed ID: 17584174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
    Rehana S; Manjunatha Kini R
    Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration.
    Fritzinger DC; Dean R; Meschter C; Wong K; Halter R; Borlak J; St John WD; Vogel CW
    Adv Exp Med Biol; 2010; 703():151-62. PubMed ID: 20711713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats.
    Proctor LM; Strachan AJ; Woodruff TM; Mahadevan IB; Williams HM; Shiels IA; Taylor SM
    Int Immunopharmacol; 2006 Aug; 6(8):1224-32. PubMed ID: 16782534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
    Eggertsen G; Lundwall A; Hellman U; Sjöquist J
    J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.